AM

Akansha Mehta

Active Director Director DIN 08053401
DIN 08053401 First appointment Jan 2018 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2018
Shareholding value •••• Premium profile

About Akansha Mehta

Data last updated:

Akansha Mehta is a Director at Ravi Pharma Trade Private Limited (since 2018). The company operates in Trading. Ravi Pharma Trade Private Limited reported revenue of ₹31.3 Lakh (FY 2024).

DIN 08053401
Primary Designation Director
Industry Trading
First Appointment 13 Jan 2018
Oldest Company Age 10 yrs
Largest company Ravi Pharma Trade Private Limited · ₹31.3 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ravi Pharma Trade Private Limited U24302RJ2016PTC054763
Director13 Jan 20182016₹31.3 Lakh (FY 2024)Active

Board colleagues of Akansha Mehta

Directorship timeline

Open interactive timeline →
Ravi Pharma Trade Private Limited
Premium access

Shareholding and investment profile for Akansha Mehta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Akansha Mehta

Akansha Mehta currently holds 1 directorship: Ravi Pharma Trade Private Limited (Director, since 13 Jan 2018, revenue ₹31.3 Lakh (FY 2024)).

Akansha Mehta was first appointed on 13 Jan 2018 as Director at Ravi Pharma Trade Private Limited.

The current boards of Akansha Mehta's companies include Ravi Kishore Mehta (Ravi Pharma Trade Private Limited), Trishla Mehta (Ravi Pharma Trade Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available